Science and Research

Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia

INTRODUCTION: Implementation of the 7-valent pneumococcal conjugate vaccine (PCV7) in infant vaccination programs has substantially reduced the burden of PCV7 serotypes also in adult community-acquired pneumonia (CAP). Currently, it is unclear, if this extensive herd protection effect can be extrapolated to the additional 6 serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13), which replaced PCV7 in Germany in 2010. OBJECTIVES: We investigated changing trends for PCV13 serotypes in adult CAP patients between three to seven years after implementation of PCV13 infant immunization in Germany. METHODS: Between December 2012 and January 2017, urine samples from German adult patients with radiologically confirmed CAP were prospectively collected by the multi-center cohort study CAPNETZ and analyzed by the serotype-specific multiplex urinary antigen detection assay (SSUAD) allowing for the detection of PCV13 serotypes. RESULTS: PCV13 serotypes were found in 59 of 796 (7.4%) patients with all-cause CAP, most prevalent was serotype 3 (30 of 59 patients, 50.8%). All patients with serotype 3-CAP were admitted to hospital and the majority required oxygen at admission (83.3% of patients with serotype 3-CAP versus 50.9% of patients with pneumococcal CAP by other serotypes, p = 0.005). Compared to SSUAD testing, conventional microbiological workup missed 27 of 30 (90.0%) serotype 3-CAP cases. We could not observe a time trend in the proportions of PCV13 serotypes and serotype 3 in all-cause CAP between 2013 and 2016 (OR trend per year 0.84, 95% CI 0.64-1.11 for PCV13 serotypes and OR trend per year 0.95, 95% CI 0.70-1.28 for serotype 3). CONCLUSIONS: Conventional methods underestimate serotype 3-CAP that can cause severe disease. Changes in overall PCV13 coverage were not detected during the years 2013 to 2016, mostly driven by a high proportion of serotype 3.

  • Forstner, C.
  • Kolditz, M.
  • Kesselmeier, M.
  • Ewig, S.
  • Rohde, G.
  • Barten-Neiner, G.
  • Rupp, J.
  • Witzenrath, M.
  • Welte, T.
  • Pletz, M. W.
  • Capnetz study group

Keywords

  • *Conjugate vaccine
  • *Herd immunity
  • *Serotype 3
  • *Serotype-specific urinary antigen detection assay
  • *Streptococcus pneumoniae
  • competing financial interests or personal relationships that could have appeared
  • to influence the work reported in this paper.
Publication details
DOI: 10.1016/j.vaccine.2019.11.026
Journal: Vaccine
Pages: 1129-1136 
Number: 5
Work Type: Original
Location: Assoziierter Partner
Disease Area: PALI
Partner / Member: CAPNETZ, UKSH (Lübeck)
Access-Number: 31761500
See publication on PubMed

DZL Engagements

chevron-down